Namenda Xr Oral Capsule, Extended Release 14Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Namenda XR: Oral capsule, extended release (14mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_18479.JPG
Namenda XR 14mg ER Capsule
Actavis- US Brands formerly Forest Pharmaceuticals Inc
Pill Identification: FLl 14 mg 

What is this Medicine?

MEMANTINE (MEM an teen) is used to treat dementia caused by Alzheimer's disease.

In-Depth Information

Namenda XR 14mg Extended-Release Capsule

NDC: 004563414
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Alzheimer's Disease

Sometimes used for but not FDA approved for the following conditions:
Nystagmus

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Namenda XR 14mg Extended-Release Capsule
Drug Image file DrugItem_18479.JPG
Actavis- US Brands formerly Forest Pharmaceuticals Inc
Pill Identification: FLl 14 mg 
Shape: capsule
Color: green,yellow

Reported Side Effects for Namenda XR 14mg Extended-Release Capsule

Fluid Retention Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Fainting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Anemia Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Secretion Of Tears Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Hyperkinesis Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Retinal Detachment Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Excessive Mucle Tone Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Nerve Pain Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Hypoesthesia Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Psychosis Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Coughing Up Blood Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Loss Of Memory Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Unable To Speak Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Breathing Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Causing To Be Hungry Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Deafness Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Melena Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Blurred Vision Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Throat Ulcers Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Emotional Lability Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Increased Sexual Desire Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Corneal Opacification Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Double Vision Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Fluid In Lungs Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Itching Incidence:
0.1-1.0%*
Severity: MILD
Onset: RAPID
Eye Pain Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Macular Degeneration Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Pressure Incidence:
0.1-2.0%*
Severity: MODERATE
Onset: RAPID
Low Blood Sodium Levels Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Drooping Eyelids Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Eczema Vaccinatum Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Painful Urination Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Bleeding In Eye Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Diabetes Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Skin Ulcer Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Delirium Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Suddenly Stopped Heart Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Slow Heart Beat Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: RAPID
Inflamed Eyes Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Irregular Heart Beat Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: EARLY
Chest Pain Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Hair Loss Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Blood In The Urine Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Intestinal Bleeding Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Low Body Temperature Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Paranoia Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Paresthesias Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Dry Eyes Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cell Counts Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Heart Attack Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Hives Incidence:
0.1-1.0%*
Severity: MILD
Onset: RAPID
Retaining Urine Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: EARLY
Irritated Blood Vessels Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: RAPID
Shaking Incidence:
0.1-1.0%*
Severity: MILD
Onset: EARLY
Ringing In Ears Incidence:
0.1-1.0%*
Severity: MILD
Onset: DELAYED
Blood Clot In Lung Incidence:
0.1-1.0%*
Severity: SEVERE
Onset: DELAYED
Nearsightedness Incidence:
0.1-1.0%*
Severity: MODERATE
Onset: DELAYED
Convulsions Incidence:
0.2-0.3%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
>1.0%*
Severity: MILD
Onset: DELAYED
Increased Urination Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Brain Attack Incidence:
>1.0%*
Severity: SEVERE
Onset: EARLY
Cataracts Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Heart Failure Incidence:
>1.0%*
Severity: SEVERE
Onset: DELAYED
Balance Problems Incidence:
>1.0%*
Severity: MILD
Onset: EARLY
Conjunctivitis Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
Incoordination Incidence:
>1.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
>2.0%*
Severity: MILD
Onset: EARLY
Distressed Incidence:
2.0-5.4%*
Severity: MILD
Onset: EARLY
Nervousness Incidence:
>2.0%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
>2.0%*
Severity: MILD
Onset: DELAYED
Vomiting Incidence:
2.0-3.0%*
Severity: MILD
Onset: EARLY
Flu Incidence:
2.0-7.1%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
>2.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Uncontrolled Urination Incidence:
2.0%*
Severity: MODERATE
Onset: EARLY
Inability To Sleep Incidence:
>2.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
>2.0%*
Severity: MODERATE
Onset: DELAYED
Tired Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Shortness Of Breath Incidence:
2.0%*
Severity: MODERATE
Onset: EARLY
Loose Stools Incidence:
2.0-5.0%*
Severity: MILD
Onset: EARLY
Weight Gain Incidence:
3.0%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
3.0-5.0%*
Severity: MODERATE
Onset: DELAYED
Drowsiness Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
3.0%*
Severity: MILD
Onset: DELAYED
Hallucinations Incidence:
3.0%*
Severity: MODERATE
Onset: EARLY
Cough Incidence:
4.0-8.9%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Lightheadedness Incidence:
5.0-7.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
6.0-8.0%*
Severity: MILD
Onset: EARLY
Confusion Incidence:
6.0%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Namenda XR

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.